Pasithea Therapeutics Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Pasithea Therapeutics Corp. on June 20, 2025. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Miami Beach, Florida. Its common stock (KTTA) and warrants (KTTAW) trade on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain standard financial statements, revenue, profit, cash flow, or debt metrics. The only financial data provided relates to the Company's At The Market (ATM) offering program:
- Previous ATM Cap: $2,076,000
- Amount Sold to Date: Approximately $2,075,688
- New ATM Cap: $4,227,000
- Additional Shares Registered: $2,151,000
Material Changes
On June 20, 2025, the Company increased the maximum aggregate offering price of shares issuable under its Sales Agreement with H.C. Wainwright & Co., LLC. The cap was raised from $2,076,000 to $4,227,000, effectively doubling the available capacity for future equity sales under this program. A prospectus supplement was filed to register the additional $2,151,000 in shares.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the standard disclosure of the equity offering expansion. The primary event is the administrative increase in the ATM facility to facilitate potential future capital raises.
Investor Verification Checklist
- Verify the current market price of KTTA to assess potential dilution from the new $2.15 million ATM capacity.
- Review the filed Prospectus Supplement (referenced in Item 8.01) for specific terms of the sales agreement.
- Confirm the Company's current cash runway and burn rate in recent 10-Q or 10-K filings to understand the necessity of this capital raise.
- Check for any concurrent filings regarding the use of proceeds from the ATM program.